# ARTBIO

> ARTBIO is a clinical-stage radiopharmaceutical company developing targeted Alpha Radioligand Therapies (ARTs) built on the lead-212 (212Pb) isotope, paired with its proprietary AlphaDirect 212Pb isolation and distributed-manufacturing technology. Founded in 2021 out of the University of Oslo and Norway's Radium Hospital by Roy Larsen and Oyvind Bruland — the scientific co-founders behind Xofigo — it operates from Cambridge, Massachusetts and Oslo. ARTBIO publishes **no API, SDK, developer portal, or machine-readable specification**. This file is generated by API Evangelist from its public website; it is not published by ARTBIO.

<!--
generated: '2026-08-06'
method: generated
source: apis.yml + https://artbio.com/ (searched https://artbio.com/llms.txt -> HTTP 404)
-->

## APIs

- No public API surface. `https://artbio.com/openapi.json`, `/swagger.json`, `/api-docs`, `/docs`, `/graphql`, `/llms.txt`, `/.well-known/agent-card.json`, `/.well-known/agent.json`, `/.well-known/security.txt`, `/.well-known/openid-configuration`, `/.well-known/oauth-authorization-server`, `/.well-known/api-catalog` and `/.well-known/ai-plugin.json` all return HTTP 404, and `api.artbio.com`, `docs.artbio.com`, `developer.artbio.com`, `portal.artbio.com`, `app.artbio.com` and `status.artbio.com` do not resolve in DNS (checked 2026-08-06).

## Pipeline

- AB001 (212Pb-NG001): lead program, Phase 1 first-in-human, metastatic castration-resistant prostate cancer.
- ABD: non-clinical, triple-negative breast cancer and head and neck squamous cell carcinoma.
- ABA (212Pb, undisclosed target): non-clinical, non-small cell lung cancer and pancreatic cancer.
- ABC (212Pb, undisclosed target): discovery stage, multiple solid tumors.
- HEARTS: discovery program, multiple solid tumors.

## Company

- [Website](https://artbio.com/)
- [Our approach / technology](https://artbio.com/our-approach)
- [Clinical trials](https://artbio.com/clinical-trials)
- [News](https://artbio.com/#news)
- [Careers](https://artbio.com/#careers)
- [Privacy policy](https://artbio.com/privacy-policy)
- [Terms of service](https://artbio.com/terms-of-service)
- [Contact](mailto:info@artbio.com)

## Artifacts

- [Domain security probe](https://raw.githubusercontent.com/api-evangelist/artbio/refs/heads/main/security/artbio-domain-security.yml): TLS/HSTS/DNSSEC/CAA/SPF/DMARC posture for artbio.com, probed by API Evangelist (TLS 1.3, HSTS max-age 31536000, SPF present, no DMARC, no DNSSEC, no CAA).

## Optional

- [LinkedIn](https://www.linkedin.com/company/artbio-inc/)
- [X / Twitter](https://twitter.com/artbio_inc)
- Note: `github.com/ARTbio` is a **different** organization — the ARTbio bioinformatics facility at the IBPS in Paris (artbio.fr) — and is not this company. `github.com/ArtBio-inc` exists but has no public repositories and no attributable metadata, so no GitHub organization is claimed here.